IntraTherapies Institute
Age Management Therapeutics
PHYSICIAN MANAGED PERSONALIZED MEDICINE PROGRAMS TRANSFORMATIVE
MEDICINE…TRANSFORMATIVE HEALTHCARE
Founded in 2001, the IntraTherapies Institute is a catalyst in the evolution of
health management and the integration of Longevity Science and Personalized
Medicine within its group of proactive health enhancement programs.
Targeting the neurobiology of aging, IntraTherapies is committed to the highest
standards in providing a platform for both preventive as well as interventional
healthcare programs, IntraTherapies’ objectives are directed toward a clinical
architecture addressing primary age-related disease categories and therapeutic
processes on multiple levels of the healthcare continuum.
Within a medical framework comprising the specialties of neurology,
endocrinology, oncology, hematology, and immunology, we strive for a
comprehensive but cost effective approach enabling a new category of healthcare,
Age Management Therapeutics. From both a preventive and interventional
perspective, we enable an evidence-based platform of comprehensive care while
providing an innovative clinical environment to foster important new medical
discoveries. Founded in 2001, the IntraTherapies Institute actively pursues the
‘leading edge’ but guided by stringent oversight from a committed medical team
interested in the progression from present day clinical choices to a near future
of significant health improvement within current time frames for patients.
The ultimate objectives are to accelerate the availability of evidence-based
clinically validated treatments to a broader population seeking the most
promising, safe and effective medical programs for disease prevention, disease
intervention and enhanced health.
We identify our primary Age Management Therapeutics programs within two
categories of conjoined healthcare:
- Neurosystemic Medicine
- EpigeneticTherapeutics
IntraTherapies addresses three of the primary components of disease which
present increasing challenges to US and global healthcare:
- Age-Related Neurodegenerative Disorders
- Late Stage Cancer Therapeutics
- Auto Immune and Inflammatory Diseases
IntraTherapies initial clinical objectives for patients provide a basis for
overall equilibrium in health status enabled by evidence-based Neurosystemic
Medicine. This approach is then conjoined with longevity science,
pharmacogenomics and personalized medicine. The Age Management Therapeutics
programs continue, further extending to preventive and interventional Epigenetic
Cancer Therapeutics, with oncologist guided programs for each patient’s
condition inclusive of Quality of Life factors. IntraTherapies Neurosystemic and
Epigenetic therapeutic platforms utilize clinically-validated modalities
directed toward optimal neurosystemic health, cancer preventive therapeutics, as
well as late stage cancer interventional programs addressing a broad range of
cancer categories.
IntraTherapies clinical alliances are also pursuing research in the emerging
area of cancer preventive and interventional vaccines.
Creating an environment that resonates with responsible clinical innovation is
our central mandate and evolving a new plateau in personalized medicine our
primary mission.
PHYSICIAN MANAGED PERSONALIZED MEDICINE PROGRAMS
CATEGORY 1 | NEUROSYSTEMIC MEDICINE I AGE MANAGEMENT
THERAPEUTICS
This program is clinically directed toward to overall neuroendocrine support and
is based on the primary principles of neuroendocrinology within a clinical
program of personalized medicine. Neurosystemic Medicine addresses a spectrum of
predictive age–related degenerative disorders and central nervous system
functions with a group of Neurometabolic / Neuroendocrine regulating programs
for optimal neuro-systemic effect coupled with neuro protective factors
targeting cognitive function with potential neuroimmune benefits to support
healthy aging.
CATEGORY 2 | CANCER PREVENTIVE THERAPEUTICS
This program is clinically directed toward Enhanced Intracellular Genetic
Immunity (EIGI) via DNA Programmable Genetic Pharmacology.
CATEGORY 3 | EPIGENETIC CANCER THERAPEUTICS
IntraTherapies epigenetic programs are based on molecular cancer genetics and
DNA Programmable Genetic Pharmacology, in conjunction with targeted combination
therapies and pathway-specific programs targeted to achieve broader cancer
interventional effect with enhanced safety at the cellular level, absent adverse
impact on major cellular pathways. This approach, based on extensive human and
other mammal studies noted below, appears to result in notable reduction of
treatment toxicity levels across primary solid tumor cancer groups,
specifically, Breast, Colon, Prostate, Non Small Cell Lung, Renal, and Ovarian
cancer when further combined with Low Dose Metronomic Chemotherapy. All
IntraTherapies treatment programs are based on oncologist / hematologist
assessment of patient history, current treatment and health profile.
IECT - IntraTherapies Epigenetic Cancer Therapeutics is a Clinical Protocol
based on Molecular cancer genetics and DNA Programmable Genetic Pharmacology
directed toward inhibiting the Growth and Replication of Human Cancer Cells,
Administered as a Monotherapy or Conjunctively with Metronomic Low Dose
Chemotherapy.
Epigenetic Cancer Therapeutics is comprised of preventive and late stage cancer
interventional therapeutic programs focused on enhanced intracellular genetic
immunity. This is achieved by the integration of epigenetic programs combined
with specific standard of care oncology medications with clinically-validated
significantly reduced toxicity levels achieved via Metronomic Low Dose
Chemotherapy.
Provided as a monotherapy or within a conjunctive treatment protocol,
IntraTherapies Epigenetic Cancer Therapeutics has clinically demonstrated the
ability to inhibit the growth, replication and proliferation of human cancer
cells via DNA Methyltransferase Inhibitors. (See list of medical research
institutions and recognized peer-reviewed publications below)
Additional neurosystemic clinical objectives include the measurable achievement
of enhanced Quality of Life in managing Mood Disorders in Chronically ill
patients.
* Note: These statements are based on published medical research data from the
National Cancer Institute and other independent accredited medical institutions
in peer-reviewed oncology / hematology publications worldwide which include:
- Indiana University School of Medicine; Indiana University Cancer Center -
Departments of Surgery and Biochemistry/Molecular Biology
- Walther Oncology Center; Cancer Epigenetics Laboratory
- Spanish National Cancer Centre-Molecular Pathology Program
- Osaka University Graduate School of Medicine – Japan.
Published data referenced in this section appear in clinical oncology journals
including:
- Cancer Research / American Association for Cancer Research;
- Current Opinion in Oncology, Journal of Pharmacological Sciences
- Elsevier Cancer Letters,
- Molecular Cancer Therapeutics
- Modern Pathology
- JNCI - Journal of the National Cancer Institute
CATEGORY 4 | PAIN MANAGEMENT THERAPEUTICS
This program is clinically directed toward Interventional Regulation of
neuro-receptor and inflammation pathways for mediating chronic pain conditions
but also including degenerative osteo-arthritis, TMJ, post-traumatic surgical
pain as well as neck / back / spine disorders, chronic scoliosis, and extending
to overall Intra-systemic mediation of multi-source chronic pain within the
musculo-skeletal network.
CATEGORY 5 | MIGRAINE INTERVENTIONAL THERAPEUTICS
This program is clinically directed toward Neuro receptor channel modulation for
aura and non-aura-based chronic migraine and headache disorders.
CATEGORY 6 | SLEEP ENHANCEMENT THERAPEUTICS
This program is clinically directed toward targeted regulation of sleep
disturbances related to circadian and other neuro mechanisms to alleviate acute
and chronic insomnia as well as other inhibitors related to quality / continuity
of sleep, and lack of restorative sleep.
CATEGORY 7 | RHEUMATOLOGY AND IMMUNO-RESTORATIVE
THERAPEUTICS
This program is clinically directed to Rheumatoid Arthritis and all
Immuno-Degenerative, Autoimmune and inflammatory Disorders resulting from the
pathophysiologies of immuno-systemic compromise and chronic inflammation. This
regimen is further directed toward inflammatory diseases such as Fibromyalgia,
Lupus, Epstein-Barr, Chronic Fatigue Syndrome and the spectrum of approximately
105 immunity-related conditions.
CATEGORY 8 I NEUROOPTIC THERAPEUTICS
This program is clinically directed toward Vision Optimization and Vascular
Support for Long Term Eye Health.
CATEGORY 9 I SPORTS AND PERFORMANCE THERAPEUTICS
This program is clinically directed toward Optimization of Circulatory, Vascular
and Pulmonary Function with stabilization of Central and Sympathetic Nervous
System.
CATEGORY 10 | INTRACELLULAR DERMAL REGENERATIVE
THERAPEUTICS
This program is clinically directed toward anti-inflammatory vascular
enhancement. It may provide dynamic oxygenation throughout all dermal/epidermal
pathways.